StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

Equities researchers at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report issued on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Shares of NASDAQ TTNP opened at $6.13 on Thursday. The firm has a 50 day moving average of $5.83 and a 200 day moving average of $6.63. Titan Pharmaceuticals has a 12-month low of $4.24 and a 12-month high of $14.80.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.